Immunomodulators and delivery systems for vaccination by mucosal routes

Trends in Biotechnology

Volumn 19, Issue 8, 2001, Pages 293-304

  Ryan, Elizabeth J ^a   Daly, Lyn M ^a   Mills, Kingston H G ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DRUG INFUSION; POLYSACCHARIDES; VACCINES;

MUCOSAL SURFACES;

IMMUNIZATION;

ADJUVANT; ALUMINUM POTASSIUM SULFATE; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; CD14 ANTIGEN; CHITOSAN; COLLECTIN; COMPLEMENT RECEPTOR; FC RECEPTOR; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIPOSOME; LIVE VACCINE; MANNOSE BINDING PROTEIN; PEPTIDOGLYCAN; PHOSPHORYL LIPID A; PLASMID DNA; POLYGLACTIN; QS 21; QUIL A; SECRETORY IMMUNOGLOBULIN; SERUM AMYLOID P; TEICHOIC ACID; TOLL LIKE RECEPTOR; TOXIN AB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; ZYMOSAN;

ANTIGEN PRESENTING CELL; BACTERIUM; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNE RESPONSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLARIZATION; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; HUMANS; MUCOUS MEMBRANE; VACCINES;

BACTERIA (MICROORGANISMS);

EID: 0035426510     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(01)01670-5     Document Type: Review

References (105)

1. Genetic immunization is a simple method for eliciting an immune response
2. Total and IgE antibody levels following booster immunization with aluminum absorbed and non-absorbed tetanus toxoid in humans
3. + Th1 cells by immunization with recombinant gp120 entrapped in biodegradable microparticles
4. Innate immunity: The virtues of a nonclonal system of recognition
5. Vaccines for mucosal immunity to combat emerging infectious diseases
6. Mucosal immunity and tolerance: Relevance to vaccine development
7. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors
8. A Toll-like receptor recognizes bacterial DNA
9. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors
10. The innate immune response of the respiratory epithelium
11. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing
12. The expanding universe of T-cell subsets: Th1, Th2 and more
13. Poliovirus-specific Th1 clones with cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in a transgenic mouse model
14. Immunobiology of dendritic cells
15. Overview of interleukin-18: More than an interferon-γ inducing factor
16. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo
17. + cytotoxic T-cell responses? A paradox revisited
18. T cell costimulation other than CD28
19. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS
20. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
21. A filarial nematode secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells
22. A relationship between the structure and function of cholera and Escherichia coli heat labile enterotoxins and their immunological activity at mucosal surfaces
23. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: Adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28
24. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins
25. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
26. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin
27. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
28. Mutants of Escherichia coli heat labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the non-toxic AB complex and enzyme activity on Th1 and Th2 cells
29. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile toxin is linked to their ADP-ribosyltransferase activity
30. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvant
31. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
32. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
33. + regulatory T-cells
34. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
35. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin
36. Detection of precursor Th cells in mesenteric lymph nodes after oral immunization with protein antigen and cholera toxin
37. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: Fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production
38. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: Cholera toxin induces a Th1-like responses to Bet v1, the major birch pollen allergen
39. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile toxin
40. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: Distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity
41. Glycosphingolipids as novel targets for T-cell suppression by the B-subunit of recombinant heat-labile enterotoxin
42. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: Role of cAMP in T cell proliferation
43. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression
44. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
45. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infection
46. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice
47. Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency
48. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
49. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
50. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages
51. The adjuvant combination of monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1
52. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration
53. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen
54. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
55. Use of CpG DNA for enhancing specific immune responses
56. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
57. Single-administration vaccines: Controlled-release technology to mimic repeated immunizations
58. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response
59. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes
60. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable polymers: Effect of formulation and route of immunization on induction of Th1 and Th2 cells
61. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae
62. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo
63. Application of liposomes for development of oral vaccines: Study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization
64. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses
65. A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses
66. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system
67. Immune stimulating complexes as mucosal vaccines
68. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
69. Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and ISCOM vaccines
70. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens
71. Immune-stimulating complexes induce an IL-12 dependent cascade of innate immune responses
72. 197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
73. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
74. Effect of chitosan on epithelial permeability and structure
75. Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice
76. Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: The involvement of CD14
77. Engineering the microflora to vaccinate the mucosa: Serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli
78. Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: Expression levels and immune responses
79. -) vaccine expressing a major leishmanial surface protein (gp 63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
80. Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors
81. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens
82. Construction and murine immunogenicity of recombinant Bacille Calmette Guerin vaccines expressing the B subunit of Escherichia coli heat labile enterotoxin
83. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis
84. In vivo expression and immunoadjuvancy of a mutant of heat labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae
85. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
86. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein
87. DNA vaccines: Immunology, applications, and optimization
88. DNA immunization confers systemic, but not mucosal, protection against enteroinvasive bacteria
89. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses
90. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses
91. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
92. Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice
93. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA
94. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein
95. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
96. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
97. Class-I restricted CTL induction by immunization with naked DNA encoding measles virus haemagglutinin
98. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses
99. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector
100. Mucosal immune responses associated with polynucleotide vaccination
101. Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10
102. A review of oral vaccination with transgenic vegetables
103. Efficacy of a food plant-based oral cholera toxin B subunit vaccine
104. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
105. Immunological memory after immunization with cholera B subunit-whole cell vaccine in Swedish volunteers